Ozempic Face? One Woman Says It Made Her Look 10 Years Younger
The internet is currently filled with personal stories and discussions about Ozempic, a popular medication used for weight loss. Some users have shared positive experiences, noting significant weight reduction and improved appearance. However, others have expressed concerns about side effects and potential health risks.
According to The New York Post, one user, Alejandra Salomon, is particularly pleased with her results. She lost 60 pounds using Semaglutide, a drug similar to Ozempic, to prepare for her sister's wedding. Salomon stated that her weight loss made her look better and that she did not need Botox or other cosmetic procedures.
Unlike many users in their 40s or older who experience "Ozempic Face", Alejandra Salomon, in her late 20s, had a different experience, with her weight loss making her look 10 years younger. "My weight loss made me look 10 years younger - no Botox needed," she said.
"Ozempic face" refers to a side effect seen in some people who lose weight rapidly using Ozempic (semaglutide). As the fat under the skin diminishes, especially in the face, it can lead to sagging skin, a gaunt appearance, or more pronounced wrinkles-making the face look older or sunken.
Conversely, some experts warn about the effects of GLP-1 drugs like Ozempic. Dr Patrick Byrne, president of the American Academy of Facial Plastic and Reconstructive Surgery, mentioned that these medications can cause the face to appear older over time.
Additionally, a recent study conducted by Oxford University involving over 6,000 people found that individuals who stop using GLP-1 drugs often regain the lost weight within ten months unless they maintain a healthy lifestyle.
While some Ozempic faces are appearing older with sunken cheeks, gaunt eyes and sagging neck skin - that doesn't seem to be the case for Saloman, as she's thrilled with how young her face looks.
"It looks like I got jawline filler, but really, I lost 60 lbs and got in the best shape of my life," she told NeedToKnow.
The 20-something-year-old started taking the weight loss drug "...because my parents thought it would be a good idea to lose 20lbs for my sister's wedding."
While some users, like Salomon, feel that these medications have positive effects on their appearance, health professionals advise caution due to possible long-term side effects.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Forget ozempic, this natural fibre mimics its effects, aiding dramatic weight loss and blood sugar control, say experts
We've all heard about Ozempic, the diabetes drug that's become popular for its strong weight loss effects. But what if a simple, natural ingredient like fibre could do something similar? That's what a new study from the University of Arizona and the University of Vienna suggests. Researchers have found that beta-glucan, a special type of fibre found in oats and barley, may help with weight loss and blood sugar control, just like Ozempic, but without any medication. For a long time, fibre wasn't the star of the nutrition world. People mostly focused on carbs and protein. But now, fibre is making a comeback, especially as we learn more about how it helps our gut and overall health. Our gut is home to trillions of tiny bacteria, known as the gut microbiome. These bacteria love fibre. In return, they help us digest food, fight off illness, and even manage weight. In the new 2024 study, scientists gave different types of fibre to mice who were on a high-fat diet. Only one type worked for weight loss: beta-glucan. Beta-glucan is a soluble fibre. That means it dissolves in water and can be easily used by gut bacteria. You can find it in common whole grains like oats and barley. In the study, mice that ate beta-glucan didn't eat less food, but they still lost weight and fat. Their metabolism changed. One of the biggest changes was an increase in a helpful gut bacterium called Ileibacterium, which other studies have also linked to weight key change was the production of a chemical called butyrate. This is made when gut bacteria digest fibre. Butyrate helps your body release GLP-1, a hormone that reduces hunger. Ozempic works by mimicking this same hormone. So in simple terms, beta-glucan might help your body make more of this hormone doesn't just help with weight. It also protects the lining of your gut, supports the liver, and may lower inflammation. Scientists say we still have a lot to learn, but the early signs are said, remember: this research was done in mice. We still need more studies in humans to be sure it works the same beta-glucan to your diet is easy. Here are some foods that naturally contain it: Oats Barley Sorghum Rye Maize (corn) Triticale (a wheat-rye hybrid) Wheat and durum wheat Rice Mushrooms Seaweed These foods slow down digestion, which keeps you full for longer and helps your body manage blood sugar better. Inputs from TOI
Time of India
2 hours ago
- Time of India
Forget ozempic, this natural fibre mimics its effects, aiding dramatic weight loss and blood sugar control, say experts
Fibre's comeback moment What's so special about beta-glucan? Live Events More than just weight loss Foods that are rich in beta-glucan Oats Barley Sorghum Rye Maize (corn) Triticale (a wheat-rye hybrid) Wheat and durum wheat Rice Mushrooms Seaweed (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel We've all heard about Ozempic , the diabetes drug that's become popular for its strong weight loss effects. But what if a simple, natural ingredient like fibre could do something similar?That's what a new study from the University of Arizona and the University of Vienna suggests. Researchers have found that beta-glucan , a special type of fibre found in oats and barley, may help with weight loss and blood sugar control , just like Ozempic, but without any a long time, fibre wasn't the star of the nutrition world. People mostly focused on carbs and protein. But now, fibre is making a comeback, especially as we learn more about how it helps our gut and overall gut is home to trillions of tiny bacteria, known as the gut microbiome . These bacteria love fibre. In return, they help us digest food, fight off illness, and even manage weight. In the new 2024 study, scientists gave different types of fibre to mice who were on a high-fat diet . Only one type worked for weight loss: is a soluble fibre. That means it dissolves in water and can be easily used by gut bacteria. You can find it in common whole grains like oats and the study, mice that ate beta-glucan didn't eat less food, but they still lost weight and fat. Their metabolism changed. One of the biggest changes was an increase in a helpful gut bacterium called Ileibacterium, which other studies have also linked to weight key change was the production of a chemical called butyrate. This is made when gut bacteria digest fibre. Butyrate helps your body release GLP-1, a hormone that reduces hunger. Ozempic works by mimicking this same hormone. So in simple terms, beta-glucan might help your body make more of this hormone doesn't just help with weight. It also protects the lining of your gut, supports the liver, and may lower inflammation. Scientists say we still have a lot to learn, but the early signs are said, remember: this research was done in mice. We still need more studies in humans to be sure it works the same beta-glucan to your diet is easy. Here are some foods that naturally contain it:These foods slow down digestion, which keeps you full for longer and helps your body manage blood sugar from TOI
The Print
4 hours ago
- The Print
Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market
Insulin is a hormone that helps move glucose (sugar) from the bloodstream into cells to stop it from building up in the bloodstream. Patients with type 1 diabetes or advanced type 2 diabetes need to administer insulin, typically multiple times a day, in order to keep their blood sugar in a healthy range. Now, with a number of Indian drugmakers foraying into the insulin market in the country once dominated by multinational drugmakers—Big Pharma, its cost is expected to dip further. New Delhi: Insulin, a lifeline for nearly all patients with type 1 diabetes and nearly 10 percent of those with type 2 diabetes, is available in India at an average cost of Rs 133 per vial—among the cheapest in the world. With the country seeing a near explosion of diabetes, the size of India's insulin market stood at an estimated Rs 4,404 crore in April this year, according to Pharmatrac, a market research company that tracks the Indian drug market. Its April report, the latest, which ThePrint has seen, said, 'Indian players are making a steady entry in the Insulins market that was once dominated by MNCs'. Four Indian companies have launched various insulin brands in India over the last two years in the segment where multinationals such as Novo Nordisk, Eli Lilly and Company and Sanofi have ruled the roost, according to Pharmatrac statistics. It added that with innovator companies like Eli Lilly and Novo Nordisk increasingly focusing on the anti-obesity segment (Mounjaro, Ozempic and Wegovy), it opens 'doors of opportunity for the Indian players' to expand their footprint. According to data from the Pharmatrac report, of over 90 insulin brands available in the Indian market, 14 have a collective market share of more than 80 percent. Of these, 11 are owned by either Novo Nordisk, which has a tie-up with Abbott for marketing them in India, or Sanofi, while one brand, Huminsulin by US-based pharma giant Eli Lilly, was sold to Indian drugmaker Lupin last year. The two best-selling insulin brands in the country include Mixtard and Ryzodeg, both by Danish drugmaker Novo Nordisk. Mixtard alone has a market of over Rs 800 crore in India. The only Indian company, which has two brands among the top-selling 14 insulin brands, is Ahmedabad-based Eris Lifesciences. Indian companies that have entered the segment since 2023 include USV, Anthem Biopharma, Cadila and Mankind. Additionally, Cipla, following a strategic tie-up with Eli Lilly, launched its insulin drug, Lyumjev, in India in October 2023. Pharmatrac statistics also showed that Indian companies, which include Eris Lifesciences, Cipla and Mankind, apart from Lupin, sold insulin worth Rs 1,088 crore between April 2024 and April 2025—24.7 percent of the total insulin market. However, as of now, a large number of diabetics in need of insulin still cannot access or afford the new generation versions that are more convenient to use, and most new brands being launched in India have yet to address this issue. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Further price crashes expected In 2023, the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation estimated that nearly 101 million people in India had diabetes. It is suggested that while the majority with the condition have type 2 diabetes, the number of those with type 1 is also estimated to be around 9 lakh, and this includes a large number of those under 18 years of age. Type 1 diabetes, say experts, is characterised by complete loss of the insulin-producing beta cells due to an autoimmune disease or idiopathic (unknown) reasons. Type 2 diabetes, also called diabetes mellitus, on the other hand, is mainly triggered by insulin resistance or the body's inability to respond to insulin, often combined with relatively reduced insulin secretion and is linked with lifestyle issues such as poor dietary habits and lack of physical activity. Nearly 10 percent of patients with type 2 diabetes, mainly those in the advanced or severe stage of the condition, require insulin, but for all patients with type 1 diabetes, insulin is mandatory, mostly 3-4 times a day Type 1 diabetes is growing at a rate of 6.7 percent annually in India, compared to 4.4 percent for type 2 diabetes, the latest Pharmatrac report noted. Diabetologist and researcher Dr V. Mohan underlined that the exact reason why the number of people with type 1 diabetes is growing may not be properly understood, but it could also be due to better awareness about the condition and quicker diagnosis. 'Earlier, many with type 1 diabetes used to die within years of disease onset as they did not get insulin on time, but now they are living longer, and those with type 2 diabetes, after living with the condition for years, typically need insulin,' he said. This is why, the clinician-researcher said, the insulin segment is growing rapidly in the country. Adding, 'More competition is always good because that will help to keep up the quality of the product and also bring down the price of the insulin.' Industry insiders said the trend of Indian firms entering the segment was mainly prompted by expiration of patents on key insulin analogues and rapid global adoption of GLP-1 analogues like semaglutide and tirzepatide, used for diabetes and obesity management 'With diabetes now recognised as a national health priority, domestic companies are investing in biosimilar innovation, scaling production capabilities, and forming strategic collaborations to secure insulin supply for the domestic market,' said Saransh Chaudhary, president (global critical care) of research-driven pharma company Venus Remedies. Innovative therapy, devices for diabetics Till the 70s the insulin used by those in need was derived from animals like pigs and cows, while the 80s saw the advent of human insulin, a type of synthetic insulin made in a laboratory that mimics the insulin our body makes. Over the last 15-20 years, insulin analogues, which are more convenient and quicker to act, have been in use in developed countries. This type of medicine is made in the same way as human insulin but is genetically altered to change the way it acts in the body. More expensive than human insulin, insulin analogues have a different chemical structure and are designed to act more rapidly, within 5-10 minutes of administration and for a longer time of up to 40 hours, ensuring ease in diabetes care. These often come in specifically designed devices such as pre-filled pens that are simply administered through a click, instead of most human insulins in vials that have to be administered as an injection. However, as these formulations are not part of the National List of Essential Medicines (NLEM) and are costlier—typically costing Rs 10,000-15,000 per month—most Indian diabetics in need of insulin therapy cannot afford them. As of now, only some basic formulations of insulin are on the NLEM, whose upper price ceilings are fixed by the government. Once protected by patent, as some of them are now off-patent, their biosimilar versions—just like generics in case of small molecule drugs—have now hit the Indian market, and it could change the affordability issue, underlined Dr Manisha Arora, director, internal Medicine at the CK Birla Hospital. 'The entry of multiple pharmaceutical companies into this space reflects the segment's growth potential and the opportunity to enhance treatment outcomes through competitive pricing and technological advancements,' she said. Increased competition could spur further innovation, improve patient-centric delivery systems, and contribute to a more sustainable and equitable diabetes care ecosystem, Arora added. (Edited by Sanya Mathur) Also Read: ICMR-led consortium seeks health tax on fat, sugar & salt-rich foods to cut adolescent obesity burden
